Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). (Q38396745)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 May 2013

Language	Label	Description	Also known as
English	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).	scientific article published on 11 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

phase II clinical trial

0 references

metastatic carcinoma

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ming-Sound Tsao

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jeremy A. Squire

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

A V Tinker

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

S Ellard

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

S Welch

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

F Moens

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

D Tu

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

E A Eisenhauer

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

H MacKay

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

0 references

publication date

11 May 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

130

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

269-274

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Upstream and downstream of mTOR

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Regulation of translation initiation by FRAP/mTOR

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Changing demographics of cervical cancer in the United States (1973-2008).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Adenocarcinoma: a unique cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.008

7 January 2021

Identifiers

10.1016/J.YGYNO.2013.05.008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23672928%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38396745&oldid=1526950425"